Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline of neurological function that eventually robs them of the ability to move, speak, eat or breathe. Now, researchers from Washington University School of Medicine in St. Louis and collaborators report that long-term use of tofersen, a new drug approved by the Food and Drug […]
New ALS drug stabilizes decline with a trend toward improved strength, mobility for some (Links to an external site)








